Abstracts tagged "medical management"

Abstract Number: PP13 • 2018 ACR/ARHP Annual Meeting
Support Groups and Patient Centred Care; Making a Difference in the Lives of People with Autoimmune and Rheumatic Conditions in Ghana
Paulina Padiki Narh¹, Abdul Aziz A. Adodo Can-Tamakloe¹ and Ida Dzifa Dey², ¹The Rheumatology Initiative tRi, Accra, Ghana, ²Department of Medicine, Rheumatology Unit, School of Medicine and Dentistry,University of Ghana, Accra, Ghana
Background/Diagnosis: I felt relieved when my diagnosis was confirmed, but upon hearing Lupus and Nephritis and no cure, I felt shattered. I was referred to…
Abstract Number: 1133 • 2018 ACR/ARHP Annual Meeting
Factors for Opioids Use in the Early Treatment Options for the Knee Osteoarthritis Patients
Soo-Kyung Cho¹, Seongmi Choi², Seul Gi Im², Hyoungyoung Kim¹, Sun-Young Jung³, Eun Jin Jang⁴ and Yoon-Kyoung Sung⁵, ¹Rheumatology, Hanyang University Hospital for Rheumatic Diseases, Seoul, Korea, Republic of (South), ²Statistics, Kyungpook National University, Daegu, Korea, Republic of (South), ³College of Pharmacy, Chung-Ang University, Seoul, Korea, Republic of (South), ⁴Information Statistics, Andong National University, Andong-si, Korea, Republic of (South), ⁵Hanyang University Hospital for Rheumatic Diseases, Seoul, Korea, Republic of (South)
Background/Purpose: Current guidelines for osteoarthritis (OA) treatment recommend a range of nonpharmacological and pharmacological interventions to alleviate pain, improve function and quality of life. Most…
Abstract Number: 449 • 2017 ACR/ARHP Annual Meeting
Medical Bugs for Pain Relief in Patients with Rheumatoid Arthritis, a Systematic Review
Rongqiang Zhang¹, Puwei Yuan², Jia Li³, Bo Dong¹, Wulin Kang³, Stephanie Hyon⁴, Raveendhara R. Bannuru⁵, William F. Harvey⁴ and Chenchen Wang⁴, ¹Shaanxi University of Chinese Medicine, Xianyang 712046, China, Xianyang, China, ²Shaanxi University of Chinese Medicine, Xianyang 712046, China, XianYang, China, ³Shaanxi University of Chinese Medicine, Xianyang, China, ⁴Rheumatology, Center of Integrative Medicine and Division of Rheumatology, Tufts Medical Center, Boston, MA, Boston, MA, ⁵Center of Integrative Medicine and Division of Rheumatology, Tufts Medical Center, Boston, MA, Boston, MA
Background/Purpose: Medical bugs, a term used to describe insects and arthropods for medical treatment, have been widely used in the past centuries for pain relief.…
Abstract Number: 3152 • 2016 ACR/ARHP Annual Meeting
Rheumatoid Arthritis (RA): Premature Use of Biologics Accelerating in United States (US)
James R. O'Dell¹, Stanley B. Cohen², J Carter Thorne³ and Ted R Mikuls⁴, ¹Department of Internal Medicine, University of Nebraska Medical Center, Omaha, NE, ²Metroplex Clinical Research Center, Dallas, TX, ³Southlake Regional Health Centre, Newmarket, ON, Canada, ⁴Internal Medicine, Division of Rheumatology, University of Nebraska Medical Center, Omaha, NE
Background/Purpose: The treatment of RA has changed dramatically in the past several decades with the advent of a large number of new biologic agents as…
Abstract Number: 123 • 2015 ACR/ARHP Annual Meeting
An Economic Evaluation of Tofacitinib (Xeljanz) Treatment in Rheumatoid Arthritis: Modeling the Cost of Treatment Strategies in the US
Lindsay Claxton¹, Matthew Taylor¹, Michelle Jenks¹, Gene Wallenstein², Alan Mendelsohn³, Jeffrey Bourret³, Amitabh Singh³ and Robert Gerber², ¹York Health Economics Consortium, University of York, York, United Kingdom, ²Pfizer Inc, Groton, CT, ³Pfizer Inc, Collegeville, PA
Background/Purpose: Tofacitinib is an oral Janus kinase (JAK) inhibitor for the treatment of rheumatoid arthritis (RA). An economic model was developed to evaluate the treatment…
Abstract Number: 1997 • 2015 ACR/ARHP Annual Meeting
Underuse of Methotrexate (MTX) in the Treatment of Rheumatoid Arthritis (RA) in the United States (US): Results of a Comprehensive Pharmaceutical Claims Analysis
James R. O'Dell¹, Melanie Rohr¹, Stanley B. Cohen², J Carter Thorne³ and Ted R. Mikuls¹, ¹University of Nebraska Medical Center, Omaha, NE, ²Metroplex Clinical Research Center, Dallas, TX, ³Southlake Regional Health Centre, Newmarket, ON, Canada
Background/Purpose: MTX is the anchor DMARD for RA treatment, but there is limited information about its appropriate use in clinical practice. This claims analysis was…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].